Natalizumab (Tysabri®)

Natalizumab (Tysabri®) is a humanized monoclonal antibody directed at alpha 4 beta 1 integrin, a lymphocyte cell surface receptor involved in cell adhesion. It is thought to act in MS by limiting the migration of lymphocytes across the blood brain barrier, thereby reducing demyelination and inflammation in the brain or spinal cord. It was found to have a dramatic effect on MS disease activity to reduce the frequency of exacerbations. The recommended dose of natalizumab for relapsing forms of MS is 300 mg by IV infusion over one hour every four weeks. Side effects include urticaria and flushing. Also, over time on therapy, there is a risk of developing progressive multifocal leukoencephalopathy (PML) caused by the JC polyomavirus. Risk appears to be higher for patients who have been treated on natalizumab over 18 months. The medication must be prescribed through the Tysabri Outreach: Unified Commitment to Health (TOUCH™) program.  Individuals who have questions about Natalizumab (Tysabri®) should contact their healthcare provider.

For more information, refer to the articles below:

VA Natalizumab Forms:

Date posted: July 17, 2012